Steven J. Quinlan, Vice President & CFO 517/372-9200 Neogen reports 21% increase in annual net income

Neogen reports 21% increase in annual net income

LANSING, Mich., July 23, 2013 Neogen Corporation (NASDAQ: NEOG) announced today that net income for its 2013 fiscal year, which ended

May 31, increased 21% from the previous year to $27,190,000. Net income in the fiscal year increased to $1.12 per share, compared to the prior year s $0.94 per share.

Neogen s revenues for its FY 2013 increased 13% to $207,528,000, up from $184,046,000 in the company s previous fiscal year. Both revenues and net income for the 2013 fiscal year established new

all-time highs for the 31-year-old company. Neogen s fourth quarter revenues were $56,006,000, a 15% increase over revenues from FY 2012 s final quarter. Net income in the fourth quarter increased 17% to $7,032,000 from $6,028,000 in FY

2012, or to $0.29 per share compared to $0.25 per share in FY 2012.

I am pleased to report that we achieved our goal of doubling our

annual revenues to over $200 million in the five years since we first reached $100 million in our 2008 fiscal year, said James Herbert, Neogen s chief executive officer and chairman. Not only did the year produce outstanding

financial performance, but we also commercialized a number of internally developed products and made a couple of acquisitions that should help enhance future growth. While hitting $200 million is a nice achievement, we view it as a guidepost that we

quickly move past, and not as a hitching post.

Neogen s gross margin increased to 52.8% of sales in its 2013 fiscal year, compared

to 50.2% of sales for FY 2012. The increase is the result of a shift in product mix toward higher margin products, including food safety diagnostics, rodenticides and acquired products. Neogen reported operating income, expressed as a percentage of

sales, of 19.6% for the 2013 fiscal year, compared to 18.3% in its prior fiscal year, largely as a result of the increased gross margin and higher revenues.

We delivered a strong finish to a terrific fiscal year with a fourth quarter that saw both our Food Safety and Animal Safety divisions reporting revenue increases in excess of 10%, said Lon

Bohannon, Neogen s president and chief operating officer. For the year, our consolidated revenue growth was broad-based, partially as a result of new products and product improvements from acquisitions and our research and development

team, and partially due to successful implementation of numerous sales and marketing programs. Prior investments in infrastructure and additional personnel paid off in fiscal year 2013, and enabled us to deliver these strong results.

The fourth quarter was the 85th quarter of the past 90 quarters that Neogen reported revenue increases as compared with the previous year

including all consecutive quarters in the last eight years.

Fiscal 2013 was another excellent year for us in generating cash and

further strengthening our balance sheet, said Steve Quinlan, Neogen s vice president and chief financial officer. These results allow us to continue to make investments in our business, such as the $10 million in cash recently used

to acquire the assets of SyrVet Incorporated, an Iowa-based veterinary instrument business.

Neogen s revenue increase for FY 2013 was led by a more than 30% increase in sales

of mycotoxin test kits and related laboratory equipment, as the company responded to large mycotoxin outbreaks in the United States and Europe in the 2012 growing season. The outbreaks coincided with the release of Neogen s new Reveal Q+ line of fully quantitative test strips that quickly and easily deliver precise results for the six major

mycotoxins, including aflatoxin and deoxynivalenol (DON). The outbreaks also coincided with the release of the company s new AccuScan Pro test strip reader that provides permanent, objective and quantitative results based on the lines that form on the simple test strips.

Sales of Neogen s innovative rapid tests for food allergens continued their strong performance, increasing more than 20% compared to the prior year.

This growth was driven by increasing global regulatory pressure on the food industry to address the issue of unlabeled food allergens (e.g., peanuts and milk) contaminating non-allergenic food products, meat speciation testing in Europe, and the

strong acceptance of the company s Reveal 3-D test kits.

Revenues for the company s Scotland-based Neogen Europe subsidiary

increased by more than 20% for FY 2013 when compared to the prior year. Sales of Neogen s test kits for meat speciation, and complementary laboratory services in Scotland, more than tripled on a year-to-year comparison as the company responded

to the horse meat scandal in Europe, where product represented as ground beef was found to contain horse and pig meat. A mycotoxin outbreak in Germany and an expansion of Neogen s genomics testing services program in Europe also helped drive

the subsidiary s increase compared to the prior year.

The company s Brazilian subsidiary recorded a more than 40% sales increase

compared to the prior year, driven by increased sales of Neogen s rapid tests for dairy antibiotics and mycotoxins; revenues from its genomic testing services also contributed to the increase. Sales at Neogen s subsidiary in Mexico

increased over 10% compared to FY 2012. Overall, approximately 40% of Neogen s total revenues for its FY 2013 were from its international markets.

The May 2012 acquisition of Igenity helped increase GeneSeek

revenues by 9% in FY 2013 compared to FY 2012. Igenity s extensive bioinformatics portfolio is used to identify positive or negative traits that allow cattle producers to make better breeding herd selections. The Igenity program has

commercialized bioinformatics to detect a number of cattle diseases that have been found to be genetically transmitted. Results from these tests allow cattle producers to make certain these genetic carriers are not used in ongoing breeding programs.

The merging of Igenity s and GeneSeek s capabilities, combined with the January 2013 acquisition of Scidera Genomics, another genomics services provider, is helping Neogen maintain a leadership position in the commercialization of animal

Sales of Neogen s rodenticides achieved significant growth in FY 2013, increasing 20% from the prior year. Rodenticide sales

were especially strong in the farm retail and animal protein market segments. Sales of Neogen s small animal supplements increased significantly in the current year when compared to the prior year, as the company responded to a temporary market

shortage of supplements used for thyroid hormone replacement therapy in dogs.

Neogen s October 2012 acquisition of

Macleod Pharmaceuticals, an animal health company headquartered in Fort Collins, Colorado, also helped bolster the company s Animal Safety segment sales. Macleod is the original manufacturer of Uniprim , a leading veterinary antibiotic. Uniprim is a prescription-only combination of trimethoprim and sulfadiazine that

provides effective antibacterial activity against a wide range of infections.

Neogen Corporation develops and markets products dedicated to

food and animal safety. The company s Food Safety Division markets dehydrated culture media, and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases and sanitation concerns.

Neogen s Animal Safety Division is a leader in the development of animal genomics along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound

care and disinfectants.

NEOGEN CORPORATION UNAUDITED SUMMARIZED CONSOLIDATED OPERATING DATA

(In thousands, except for per share and percentages)

NEOGEN CORPORATION SUMMARIZED CONSOLIDATED BALANCE SHEET DATA

Certain portions of this news release that do not relate to historical financial information constitute

forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in

Management s Discussion and Analysis of Financial Condition and Results of Operations in the Company s most recently filed Form 10-K.